资讯
内科
心血管
肿瘤
内分泌
普通内科
消化
呼吸
神经科
传染科
精神心理
肾内科
风湿免疫
血液科
老年医学
外科
头颈外科
胃肠外科
血管外科
肝胆胰外
骨科
普通外科
胸心外科
神经外科
泌尿外科
烧伤科
整形美容
麻醉疼痛
专科科室
罕见病
康复医学
药械
儿科
耳鼻咽喉
口腔科
眼科
政策人文
营养全科
预防公卫
妇产科
中医科
急重症
皮肤性病
影像放射
转化医学
检验病理
护理
热点
临床研究
研究设计
人工智能
智慧医疗
论文基金
医学科普
药物经济
医生集团
职业安全
患者招募
医学科研
公司产业
医学英语
MedSci动态
指南
按科室浏览
肿瘤科
心血管
传染科
妇产科
神经科
儿科
呼吸
内分泌科
血液科
消化
更多科室
工具
临床工具
临床指南
医学计算与公式
ICD-10/ICD-11疾病编码
医讯达
直播
话题
公开课
精品课
科研工具
期刊数据库查询
期刊智能选择
全球基金查询
文献查询
SCI写作宝典
生物医药大词典
其他工具
下载App使用方便更快捷
Medsci 梅斯搜索
公开课
精品课
服务
科研数智化
直播,公开课与精品课
科研加速器
研究者发起的临床研究(IIS)支持
真实世界研究解决方案
药物经济学
医保准入事务
研究方案设计
数据库建立与管理
药物警戒(PV)
真实世界研究执行
数据统计分析
数字化学术传播解决方案
多渠道营销(MCM)
产品医学策略
学术传播(APO)
其它
积分商城
FAQS
map
#Xtandi#
17篇内容 | 1168人围观
关注话题
话题活跃用户
#
插入话题
插入图片
评论
最新
最热
GetTopicDetailResponse(id=64ab18861b7, topicName=Xtandi, introduction=Xtandi, content=null, image=null, comments=17, allHits=1168, url=https://h5.medsci.cn/topic?id=18861, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=32710, tagList=[TagDto(tagId=32710, tagName=Xtandi)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1653719, encodeId=1a891653e19ee, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=转移性激素敏感型前列腺癌如何治疗?XTANDI(enzalutamide)有望获得欧盟批准, objectType=article, longId=209089, objectId=845f2090899d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=845f2090899d, replyNumber=0, likeNumber=62, createdTime=2021-06-09, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=845f2090899d, moduleTitle=转移性激素敏感型前列腺癌如何治疗?XTANDI(enzalutamide)有望获得欧盟批准, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=845f2090899d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653718, encodeId=2af61653e18be, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=NMPA批准XTANDI(恩杂鲁胺软胶囊)治疗非转移性去势抵抗性前列腺癌, objectType=article, longId=203137, objectId=f21a20313e8c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f21a20313e8c, replyNumber=0, likeNumber=87, createdTime=2021-03-02, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f21a20313e8c, moduleTitle=NMPA批准XTANDI(恩杂鲁胺软胶囊)治疗非转移性去势抵抗性前列腺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f21a20313e8c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653717, encodeId=55ca1653e173a, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=前列腺癌治疗的ORIC-101联合XTANDI的Ib期临床试验正式开始, objectType=article, longId=186929, objectId=70311869299e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70311869299e, replyNumber=0, likeNumber=90, createdTime=2020-06-30, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70311869299e, moduleTitle=前列腺癌治疗的ORIC-101联合XTANDI的Ib期临床试验正式开始, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=70311869299e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653715, encodeId=74c41653e15c2, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=Xtandi成**获批FDA 前列腺癌口服疗法, objectType=article, longId=184883, objectId=a45f1848839f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a45f1848839f, replyNumber=0, likeNumber=74, createdTime=2020-06-29, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a45f1848839f, moduleTitle=Xtandi成**获批FDA 前列腺癌口服疗法, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a45f1848839f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653716, encodeId=120a1653e1613, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=恩杂鲁胺Xtandi获FDA批准用于治疗转移性去势敏感性前列腺癌, objectType=article, longId=184900, objectId=b47618490022, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b47618490022, replyNumber=0, likeNumber=67, createdTime=2020-05-21, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b47618490022, moduleTitle=恩杂鲁胺Xtandi获FDA批准用于治疗转移性去势敏感性前列腺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b47618490022)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653714, encodeId=5cc91653e148e, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=恩杂鲁胺XTANDI治疗转移性前列腺癌获得FDA的优先审查, objectType=article, longId=178215, objectId=9f1f1e821593, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f1f1e821593, replyNumber=0, likeNumber=71, createdTime=2019-10-08, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f1f1e821593, moduleTitle=恩杂鲁胺XTANDI治疗转移性前列腺癌获得FDA的优先审查, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9f1f1e821593)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653713, encodeId=82311653e1359, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=XTANDI治疗转移性激素敏感性前列腺癌患者的III期ARCHES试验取得阳性结果, objectType=article, longId=156671, objectId=78e61566e182, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78e61566e182, replyNumber=0, likeNumber=92, createdTime=2019-06-29, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78e61566e182, moduleTitle=XTANDI治疗转移性激素敏感性前列腺癌患者的III期ARCHES试验取得阳性结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=78e61566e182)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653712, encodeId=281d1653e12b3, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=FDA扩大了辉瑞/安斯泰来的Xtandi的适应症用以治疗非转移性前列腺癌, objectType=article, longId=144569, objectId=4e5f14456932, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e5f14456932, replyNumber=0, likeNumber=92, createdTime=2018-12-17, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e5f14456932, moduleTitle=FDA扩大了辉瑞/安斯泰来的Xtandi的适应症用以治疗非转移性前列腺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4e5f14456932)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653711, encodeId=97f61653e11e2, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=辉瑞/Astellas的Xtandi降低前列腺癌的扩散风险, objectType=article, longId=129145, objectId=e88a1291455c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e88a1291455c, replyNumber=0, likeNumber=69, createdTime=2018-05-26, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e88a1291455c, moduleTitle=辉瑞/Astellas的Xtandi降低前列腺癌的扩散风险, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e88a1291455c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653710, encodeId=a15e1653e10d8, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=FDA受理安斯泰来新一代前列腺癌口服药物Xtandi补充新药申请, objectType=article, longId=64043, objectId=8f426404391, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f426404391, replyNumber=0, likeNumber=74, createdTime=2016-07-14, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f426404391, moduleTitle=FDA受理安斯泰来新一代前列腺癌口服药物Xtandi补充新药申请, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8f426404391)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653709, encodeId=f2b81653e09be, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=重磅!强生Zytiga霸主地位不保,安斯泰来前列腺癌药物Xtandi拿下欧美2大市场, objectType=article, longId=43576, objectId=d305435e687, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d305435e687, replyNumber=0, likeNumber=86, createdTime=2015-06-15, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d305435e687, moduleTitle=重磅!强生Zytiga霸主地位不保,安斯泰来前列腺癌药物Xtandi拿下欧美2大市场, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d305435e687)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653705, encodeId=f1531653e055b, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=安斯泰来前列腺癌新药Xtandi III期PREVAIL达主要终点, objectType=article, longId=25824, objectId=c92d2582476, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c92d2582476, replyNumber=0, likeNumber=88, createdTime=2014-08-02, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c92d2582476, moduleTitle=安斯泰来前列腺癌新药Xtandi III期PREVAIL达主要终点, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c92d2582476)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653704, encodeId=cf1f1653e0446, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=英国NICE推荐安斯泰来前列腺癌药物Xtandi用于国家卫生系统, objectType=article, longId=25579, objectId=a864255e9c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a864255e9c2, replyNumber=0, likeNumber=77, createdTime=2014-05-24, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a864255e9c2, moduleTitle=英国NICE推荐安斯泰来前列腺癌药物Xtandi用于国家卫生系统, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a864255e9c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653708, encodeId=e80c1653e0862, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=安斯泰来和Medivation向FDA提交前列腺癌药物Xtandi sNDA, objectType=article, longId=32113, objectId=e95932113e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e95932113e6, replyNumber=0, likeNumber=66, createdTime=2015-01-28, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e95932113e6, moduleTitle=安斯泰来和Medivation向FDA提交前列腺癌药物Xtandi sNDA, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e95932113e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653707, encodeId=85511653e07c3, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=安斯泰来和Medivation启动Xtandi III期PROSPER试验, objectType=article, longId=27671, objectId=50962e6713b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50962e6713b, replyNumber=0, likeNumber=74, createdTime=2014-03-14, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50962e6713b, moduleTitle=安斯泰来和Medivation启动Xtandi III期PROSPER试验, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=50962e6713b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653706, encodeId=5b131653e06de, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=安斯泰来与Medivation启动前列腺癌新药Xtandi IV期研究, objectType=article, longId=26618, objectId=c1e3266180b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1e3266180b, replyNumber=0, likeNumber=70, createdTime=2014-07-21, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1e3266180b, moduleTitle=安斯泰来与Medivation启动前列腺癌新药Xtandi IV期研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c1e3266180b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653703, encodeId=7ff31653e03a0, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=FDA批准治疗晚期前列腺癌新药Xtandi, objectType=article, longId=9511, objectId=f334951169, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f334951169, replyNumber=0, likeNumber=71, createdTime=2013-04-20, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f334951169, moduleTitle=FDA批准治疗晚期前列腺癌新药Xtandi, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f334951169)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯话题小助手
关注
已关注
Xtandi
2020-05-29
lingaifan
(审核中...)
关注
已关注
前往app查看评论内容
#Xtandi#
转移性激素敏感型前列腺癌如何治疗?XTANDI(enzalutamide)有望获得欧盟批准
62
0
2021-06-09
回复
lingaifan
(审核中...)
关注
已关注
前往app查看评论内容
#Xtandi#
NMPA批准XTANDI(恩杂鲁胺软胶囊)治疗非转移性去势抵抗性前列腺癌
87
0
2021-03-02
回复
lingaifan
(审核中...)
关注
已关注
前往app查看评论内容
#Xtandi#
前列腺癌治疗的ORIC-101联合XTANDI的Ib期临床试验正式开始
90
0
2020-06-30
回复
lingaifan
(审核中...)
关注
已关注
前往app查看评论内容
#Xtandi#
Xtandi成**获批FDA 前列腺癌口服疗法
74
0
2020-06-29
回复
lingaifan
(审核中...)
关注
已关注
前往app查看评论内容
#Xtandi#
恩杂鲁胺Xtandi获FDA批准用于治疗转移性去势敏感性前列腺癌
67
0
2020-05-21
回复
lingaifan
(审核中...)
关注
已关注
前往app查看评论内容
#Xtandi#
恩杂鲁胺XTANDI治疗转移性前列腺癌获得FDA的优先审查
71
0
2019-10-08
回复
lingaifan
(审核中...)
关注
已关注
前往app查看评论内容
#Xtandi#
XTANDI治疗转移性激素敏感性前列腺癌患者的III期ARCHES试验取得阳性结果
92
0
2019-06-29
回复
lingaifan
(审核中...)
关注
已关注
前往app查看评论内容
#Xtandi#
FDA扩大了辉瑞/安斯泰来的Xtandi的适应症用以治疗非转移性前列腺癌
92
0
2018-12-17
回复
lingaifan
(审核中...)
关注
已关注
前往app查看评论内容
#Xtandi#
辉瑞/Astellas的Xtandi降低前列腺癌的扩散风险
69
0
2018-05-26
回复
lingaifan
(审核中...)
关注
已关注
前往app查看评论内容
#Xtandi#
FDA受理安斯泰来新一代前列腺癌口服药物Xtandi补充新药申请
74
0
2016-07-14
回复
lingaifan
(审核中...)
关注
已关注
前往app查看评论内容
#Xtandi#
重磅!强生Zytiga霸主地位不保,安斯泰来前列腺癌药物Xtandi拿下欧美2大市场
86
0
2015-06-15
回复
lingaifan
(审核中...)
关注
已关注
前往app查看评论内容
#Xtandi#
安斯泰来前列腺癌新药Xtandi III期PREVAIL达主要终点
88
0
2014-08-02
回复
lingaifan
(审核中...)
关注
已关注
前往app查看评论内容
#Xtandi#
英国NICE推荐安斯泰来前列腺癌药物Xtandi用于国家卫生系统
77
0
2014-05-24
回复
lingaifan
(审核中...)
关注
已关注
前往app查看评论内容
#Xtandi#
安斯泰来和Medivation向FDA提交前列腺癌药物Xtandi sNDA
66
0
2015-01-28
回复
lingaifan
(审核中...)
关注
已关注
前往app查看评论内容
#Xtandi#
安斯泰来和Medivation启动Xtandi III期PROSPER试验
74
0
2014-03-14
回复
lingaifan
(审核中...)
关注
已关注
前往app查看评论内容
#Xtandi#
安斯泰来与Medivation启动前列腺癌新药Xtandi IV期研究
70
0
2014-07-21
回复
lingaifan
(审核中...)
关注
已关注
前往app查看评论内容
#Xtandi#
FDA批准治疗晚期前列腺癌新药Xtandi
71
0
2013-04-20
回复
共17条
首页
上一页
下一页
尾页
页码:
1
/1页
20条/页
扫描二维码下载梅斯医学APP
map
科室
订阅+
更多科室
工具
服务
map
map